Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8.

According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was announced on April 25 and included about 5,900 abstracts. Nearly 50 original domestically produced innovative drugs were selected for oral reports, more than doubling from 23; clinical studies of 5 original domestically produced innovative drugs were included in the latest breakthrough research (LBA). Huatai Securities believes that the global competitiveness of domestically produced innovative drugs has gradually been shown. They are in the first tier of the world in terms of clinical results and target/mechanism layout, and the innovative drug industry is expected to move towards a pillar industry in the future.

Zheshang Securities pointed out that the results of the 2023 innovative drug health insurance negotiations had a high success rate and moderate decline, which shows that the policy favors and supports innovative drugs. We look forward to further standardization and support for the innovative drug industry. Innovative drugs have formed a relatively stable pace of negotiations and price expectations, and we continue to be optimistic about medium- to long-term investment opportunities in the innovative drug industry. We look forward to the implementation and implementation of more full-chain support documents for the innovative drug industry to support the higher quality and sustainable development of the innovative drug industry.